Quectel’s Ultra-high Bandwidth 5G R16 Module Certified for Use on T-Mobile’s 5G and LTE-A Networks
Quectel Wireless Solutions, a global IoT solutions provider, has announced that its 5G NR module RM520N-GL, compliant with 3GPP Release 16 (R16) standards, has been certified to operate on T-Mobile’s 5G and LTE-A networks in the United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220829005280/en/
Quectel's 5G module RM520N-GL and its IoT application scenarios (Photo: Business Wire)
With this certification, RM520N-GL customers can commercially deploy their home gateways, industrial routers, industrial automation devices, unmanned delivery vehicles, robots, drones, consumer and industrial laptops and other next generation IoT applications on T-Mobile’s 5G and LTE-A networks.
“We are thrilled to see that Quectel has made further significant progress in 5G, as our module supporting 5G R16 features has gained this important certification in the North American market,” said Norbert Muhrer, President and CSO of Quectel. “This confirms our commitment to drive innovation and provide our global customers with highly reliable, best-in-class IoT solutions, which will help accelerate the next wave of 5G IoT applications.”
Based on Qualcomm’s SDX62 platform, the RM520N-GL supports both 5G NSA and SA modes, as well as R16 enhanced features such as ultra-high bandwidth, millisecond-level latency, 5G network slicing and ultra-reliability.
Targeting global markets, this module is designed to support 28 major sub-6GHz bands worldwide (n1/ 2/ 3/ 5/ 7/ 8/ 12/ 13/ 14/ 18/ 20/ 25/ 26/ 28/ 29/ 30/ 38/ 40/ 41/ 48/ 66/ 70/ 71/ 75/ 76/ 77/ 78/ 79), is backwards compatible with LTE-A/3G networks and features integrated GNSS for location services. This highly integrated module can significantly enhance customers' global IoT deployments.
Designed in an industry-standard M.2 form factor, the dimensions of the RM520N-GL are 30.0mm x 52.0mm x 2.3mm, making it pin-to-pin compatible with Quectel’s 5G module RM50xQ series, LTE-A Cat 6 module EM06/ EM060K series, Cat 12 modules EM12/ EM12xR/ EM120K series and Cat 16 module EM160R-GL, which facilitates easy network upgrades of customer devices.
The RM520N-GL supports downlink and uplink NR 2 x Carrier Aggregation (CA) and all three combinations of sub-6GHz time division duplex (TDD) and frequency division duplex (FDD) CA, including CA of FDD+TDD, FDD+FDD and TDD+TDD. This ensures greater 5G coverage, capacity and throughput by enabling the combination of available 5G spectrum assets. These features enable the RM520N-GL to have maximum downlink rates of up to 3.4Gbps and maximum uplink rates of up to 900Mbps. These data rates meet the needs of industry applications requiring enhanced mobile broadband and reliable communication capabilities, such as fixed wireless access (FWA), mobile broadband equipment and industrial automation.
Featuring a rich set of internet protocols, the RM520N-GL supports multiple optional functions including eSIM and VoLTE and integrates USB 3.1/ PCIe 3.0 super speed interfaces.
In addition to the T-Mobile approval, Quectel’s RM520N-GL has also achieved worldwide certification from GCF, PTCRB, CE, CCC, RCM, FCC and IC.
In order to help customers simplify their designs, Quectel also provides a full range of off-the-shelf and customized 5G antennas which boost wireless connectivity significantly. IoT developers can bundle the RM520N-GL module with Quectel’s antennas and pre-certification services, reducing both cost and time-to-market for their 5G devices.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.Quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005280/en/
Contact information
Media
Ashley Liu – media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom